Prevalence of hepatitis C among Aboriginal Australians

Australasian Viral Hepatitis Conference

September 2016

Simon Graham, Mary Ellen Harrod, Jenny Iversen, Jane Hocking
Simon Graham

- Simon was the first Aboriginal person to be awarded a PhD via the Kirby Institute
- Simon is currently in New York City on Fulbright Post-Doctoral Fellowship
The greater level of substance misuse among Aboriginal and Torres Strait Islander people reflects the history of dispossession and oppression of Indigenous people.

*J Ward, APSAD 2015*
Background

• There are ~713,000 Aboriginal people in Australia\(^1\)
  – ~3% of the Australian population

• Aboriginal people experience significant disadvantage:\(^2,3\)
  – More likely to use drugs (17% of IDRS sample)
  – More likely to inject drugs (up to 14% of ANSPS)
  – More likely to be on OST (10% of clients)
  – More likely to share injecting equipment (21% vs 16%, p<0.01)
  – More likely to inject on a daily basis (61% vs 53%, p<0.01)
  – Far more likely to be prison (15 x depending on jurisdiction)
  – 10 times more likely to have a sexually transmissible infection
  – 2 times more likely to be unemployed, 3 times more likely to be a daily smoker, 6 times as likely to be teenage mothers

Background – increasing epidemic in Aboriginal and Torres Strait Islander Peoples

In 2015, HCV notification rates in Aboriginal people were 4 times higher than for non-Aboriginal people\(^4\)
Background – Study Rationale

• However, there are limitations in the national surveillance system in reporting on hepatitis C prevalence:  

  • The States with the largest Aboriginal population, NSW & QLD do not report Aboriginal status

  • Only 4 of the 8 states are included in reporting HCV notifications by Aboriginal status

4. Kirby Institute. Bloodborne Viral and STI in Aboriginal and Torres Strait Islander people. 2015. Kirby Institute, UNSW Australia.
Aims

1. To estimate the pooled prevalence of hepatitis C

2. If possible, to estimate the pooled prevalence by:
   - Gender
   - Age
   - Population group
   - Risk behaviour
Methods

1. We followed the PRISMA statement guidelines\textsuperscript{5}

2. Literature search:
   - Pubmed, Web of Science, Medline,
   - New South Wales Public Health Bulletin
   - Northern Territory Public Health Bulletin
   - Abstracts from the 2010-2014 Viral Hepatitis Conferences

3. MeSH search terms:
   - Hepatitis C, HCV, anti-HCV, anti-hepatitis C, hepatitis
   - Aboriginal OR Indigenous
   - Australia

\textsuperscript{5} Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. \textit{BMJ.} 2009;\textbf{339}:b2535.}
Methods

1. Inclusion criteria:
   - Number of people testing positive / number of people tested

2. Reporting prevalence for Aboriginal people (excluded non-Aboriginal people)

3. A meta-analysis was conducted if there were more than three prevalence estimates per sub-group

4. Strategy used to assess between study heterogeneity:\(^6\)
   - \(I^2<25\%\), fixed effects meta-analysis to estimate the prevalence
   - \(I^2>25\%\), random effects meta-analysis to estimate prevalence

---

Flow diagram

**Identification**
- Studies identified through database searches:
  1. Pubmed (n=19)
  2. Web of science (n=32)
  Total (n=51)
- Studies identified through other sources:
  1. Conference abstracts (n=2)
  2. NSW Health Bulletins (n=1)
  3. Aboriginal & Islander Journal (n=0)
  Total (n=3)

**Screening**
- Number of duplicates (n=23)
- Studies screened (n=54)

**Eligibility**
- Studies excluded (n=39)
  Reasons:
  1. Not HCV (n=1)
  2. No prevalence estimate (n=19)
  3. Only anti-HCV positive people (n=9)
- Studies included (n=15)

**Included**
- Longitudinal cohorts (n=5)
- Cross-sectional studies (n=10)

**Figure 1. Flow chart of included studies**

Results

• Study design
  • 3 were longitudinal studies
  • 12 were cross-sectional studies

• Geographical location
  • 1 in a remote area
  • 2 in regional areas
  • 2 in urban areas
  • 10 were national analyses or include multiple jurisdictions

• High risk behaviour
  • 11 of the 15 studies had participants at high risk of HCV infection (e.g. people who inject drugs & people in prison)
Results

• Study population-groups:
  • 8 studies included people in prison
  • 3 studies included people who inject drugs who attended an NSP
  • 2 studies were among adults
  • 1 study was among haemodialysis patients
  • 1 study was among people diagnosed with hepatocellular carcinoma (HCC)
Prevalence of hepatitis C among Aboriginal people who inject drugs

Pooled prevalence = 58.7%, (95% CI: 53.8-63.5%), I²=19.3%, p=0.290
Prevalence of hepatitis C among Aboriginal people in prison

Prison studies from 1997-2004

Author, year

Templeton, 2010

Butler, 1999

Butler, 1997

Prevalence (%)

Pooled prevalence = 25.7%, (95% CI: 4.1-47.3%), \( I^2=95.1\% \), \( p<0.05 \)
Prevalence of hepatitis C among Aboriginal people in prison

Prison studies from 2005-2014

Pooled prevalence = 14.5%, (95% CI: 1.7-27.3%), I²=99.2%, p<0.05
Prevalence of hepatitis C among Aboriginal people in prison by period

- **Prison studies between 1997-2004**
  - 25.7%, (95% CI: 4.1-47.3%), I²=95.1%, p<0.05

- **Prison studies between 2005-2014**
  - 14.5%, (95% CI: 1.7-27.3%), I²=99.2%, p<0.05

- **Overall**
  - 18.4%, (95% CI: 8.0-28.8%), I²=98.8%, p<0.05
Limitations

• Heterogeneity
  • Prison studies had a significant degree of heterogeneity ($I^2 > 90\%$)
    • reducing the reliability of the pooled estimates
  • PWID studies had a low level of heterogeneity ($I^2 = 19.3\%, p=0.29$)

• Selection bias
  • Some individuals actively sought health services
  • Some could have identified themselves as having a risk for HCV
  • Some individuals attended NSPs
  • Some were in prison, where no NSPs exist and sharing is common
  • Our study estimates the prevalence of hepatitis C among high risk individuals and NOT the general Aboriginal population
Discussion

- Prevalence of hepatitis C was:
  - 58.7% among Aboriginal people (our review)
  - 62.0% among Aboriginal people (Australian NSP survey report)\(^7\)
- Increasing prison population and increasing proportion of Aboriginal people in prison could explain the reduction of HCV prevalence (prison population more reflective of general population):\(^8\)
- Drug are available in prisons - around half of prisoners with a history of injecting drug use will inject while incarcerated\(^8\)
  - Some people initiate injecting in prison

---

Recommendations – Monitoring and Treatment

• Monitoring
  • Improve monitoring systems to include Aboriginal and Torres Strait Islander identification to support targeted and effective resources

• Treatment
  • Culturally appropriate promotion and information about the new treatments
  • Increased support to deliver new treatment in low-threshold settings (NSP, AMS)
  • Peer support to access testing and treatment
Recommendations: Prevention

• **Prevention in Prison**
  
  *Prisoners shall have access to the health services available in the country without discrimination on the grounds of their legal situation (UN Charter)*
  
  – Access to NSPs
  – Equal access to OST

• **Community access to NSP and OST**
  
  – NSP services are generally good in Australia but there are many rural communities with very significant issues for Aboriginal people who inject drugs

• **Consideration on how to safeguard communities while their members cycling in and out of prison**
Conclusions

• High prevalence of hepatitis C in Aboriginal People a human rights issue
• We must remember that stigma is driving the HCV epidemic and we will only eliminate HCV if we provide equitable access to health care and address stigma
• It’s complex, it won’t be easy to address
  • The entrenched social and economic marginalisation in Aboriginal and Torres Strait Islander people requires holistic and well-funded strategies to address the underlying social determinants of Indigenous ill-health (JW)
Published paper

Prevalence of Hepatitis C Among Australian Aboriginal and Torres Strait Islander people: A Systematic Review and Meta-Analysis

Simon Graham,1 Mary-Ellen Harrod,2 Jenny Iversen,3 and Jane Simone Hocking1

1Center for epidemiology and biostatistics, school of population and global health, university of Melbourne, Melbourne, Victoria, Australia
2New South Wales Liver and AIDS Association, Sydney, New South Wales, Australia
3Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

Corresponding author: Simon Graham, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Tel: +61 3 83441212, Email: simon.graham@unimelb.edu.au

Received 2016 April 22; Revised 2016 May 18; Accepted 2016 June 13

Abstract

**Context:** Aboriginal and Torres Strait Islanders (Aboriginal) account for approximately 2% of the Australian population. They have the poorest health, economic and social outcomes. Higher notification rates of hepatitis C antibodies (anti-HCV) have been reported among Aboriginal compared with non-Aboriginal people. The identification of Aboriginal people in national surveillance has some weaknesses, with only four of the eight jurisdictions included in national reporting. To address some of these limitations, we aim to estimate the pooled prevalence of anti-HCV among Aboriginal people in Australia.

**Evidence Acquisition:** We searched the databases: PubMed, Web of Science and Informit, and the New South Wales and Northern Territory Public Health Bulletins. A study was included if it reported the number of Aboriginal people testing positive for anti-HCV and the number tested for anti-HCV. A meta-analysis by population group was conducted if three or more studies reported a prevalence estimate. Variables included: author, year of publication, study design, study period, gender (female, male), age, population group (Aboriginal people in prison, Aboriginal people who inject drugs), number tested anti-HCV positive, number tested for anti-HCV and prevalence (%). Due to a long time period, we separated the studies estimating the prevalence anti-HCV among Aboriginal people in prison into two time periods, 1994 - 2004 and 2005 - 2012.
Acknowledgements

• Simon Graham
  – McKenzie postdoctoral fellowship, University of Melbourne
  – Melbourne Poche Centre for Indigenous Health

• Jenny Iversen & Jane Hocking
  – NHMRC fellowships

• Mary Ellen Harrod
  – NSW Ministry of Health
Thank you